Abstract
Some of the antagonists of growth hormone-releasing hormone (GHRH) are able to inhibit the growth of various experimental human cancers. The antitumor effects of first antagonists seemed to be dependent mainly on the disruption of pituitary secretion of growth hormone (GH), followed by the reduction in the levels of circulating insulin-like growth factor (IGF)-1, an important growth factor for cancer cells. It seems obvious, that growth hormone deficiency (GHD) induced by GHRH antagonists with all its complications, could limit the beneficial effects of GHRH antagonists therapy, and decrease patients quality of life. The discovery of local autocrine/paracrine production of GHRH and other related growth factors in many tumoral tissues, in combination with the wide expression of GHRH receptors on cancer cells, directed the research to the synthesis of more potent GHRH antagonists. These compounds exert strong inhibitory effects directly on tumor growth, with scarce endocrine action. The receptor-mediated mechanisms comprise complex and still not completely understood effects on intracellular signaling pathways that are strictly related to human tumorigenesis. This review summarizes recent patents and latest observations on the antineoplastic role of GHRH antagonists in human tumors with emphasis on potential therapeutic applications in clinical oncology.
Keywords: Cancer therapy, GHRH, GHRH antagonists, IGF-I, IGF-II, antitumor effects, pituitary secretion, oncology, intracellular signaling pathways, tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery
Title: Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Volume: 7 Issue: 1
Author(s): Agnieszka Siejka, Hanna Lawnicka, Gabriela Melen-Mucha, Ewelina Motylewska, Jan Komorowski and Henryk Stepien
Affiliation:
Keywords: Cancer therapy, GHRH, GHRH antagonists, IGF-I, IGF-II, antitumor effects, pituitary secretion, oncology, intracellular signaling pathways, tumorigenesis
Abstract: Some of the antagonists of growth hormone-releasing hormone (GHRH) are able to inhibit the growth of various experimental human cancers. The antitumor effects of first antagonists seemed to be dependent mainly on the disruption of pituitary secretion of growth hormone (GH), followed by the reduction in the levels of circulating insulin-like growth factor (IGF)-1, an important growth factor for cancer cells. It seems obvious, that growth hormone deficiency (GHD) induced by GHRH antagonists with all its complications, could limit the beneficial effects of GHRH antagonists therapy, and decrease patients quality of life. The discovery of local autocrine/paracrine production of GHRH and other related growth factors in many tumoral tissues, in combination with the wide expression of GHRH receptors on cancer cells, directed the research to the synthesis of more potent GHRH antagonists. These compounds exert strong inhibitory effects directly on tumor growth, with scarce endocrine action. The receptor-mediated mechanisms comprise complex and still not completely understood effects on intracellular signaling pathways that are strictly related to human tumorigenesis. This review summarizes recent patents and latest observations on the antineoplastic role of GHRH antagonists in human tumors with emphasis on potential therapeutic applications in clinical oncology.
Export Options
About this article
Cite this article as:
Siejka Agnieszka, Lawnicka Hanna, Melen-Mucha Gabriela, Motylewska Ewelina, Komorowski Jan and Stepien Henryk, Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists, Recent Patents on Anti-Cancer Drug Discovery 2012; 7 (1) . https://dx.doi.org/10.2174/157489212798358010
DOI https://dx.doi.org/10.2174/157489212798358010 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
All for Statins and Statins for All; An Update
Current Pharmaceutical Design Imaging Cellular Receptors in Breast Cancers: An Overview
Current Pharmaceutical Biotechnology Decreased Serum Adiponectin Level Affected Clinical Pathological Characteristics of Patients with Gastric Cancer
Current Proteomics Research Advancements in Porcine Derived Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Gonadotropin-Releasing Hormone Receptor Signaling: Biased and Unbiased
Mini-Reviews in Medicinal Chemistry Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Bacterial Biotransformation and Anticancer Activities of Betulin against A549, HepG2 and 5RP7 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics and Disposition of Nanomedicine Using Biodegradable PEG/PCL Polymers as Drug Carriers
Current Drug Metabolism Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Emerging Role of Apelin as a Therapeutic Target in Cancer: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry Some Developments Regarding Functional Food Products (Functional Foods)
Current Nutrition & Food Science Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design